Peculiarities of anticoagulant therapy for venous thrombosis and chronic renal insufficiency (literature review)
AbstractThe choice of antithrombotic therapy for treatment of patients with venous thromboses and renal dysfunction supposes a special approach due to increased risk of both hemorrhagic and thrombotic events. Therapeutic decision-making is difficult because of concomitant renal dysfunction. Improved quality of life and prognosis in elderly patients with chronic renal insufficiency largely depend on adequate anticoagulant therapy with modern drugs.
Presented herein are the findings of several studies in patients with deep vein thrombosis/pulmonary embolism, receiving therapy including that with rivaroxaban, demonstrating its high anticoagulation effect and a favorable safety profile as low risks of hemorrhage in high-risk patients, i. e., those with renal dysfunction, as well as in frail patients.
Keywords: acute venous thrombosis; chronic renal insufficiency; anticoagulant therapy, direct oral anticoagulants; rivaroxaban; apixaban; dabigatran; edoxaban
Funding. The study had no financial support.
Conflict of interest. The publication was supported by the “Bayer” Company.
Authors’ contribution. Study conception and design – Repin A.A., Katorkin S.E.; data collection and handling – Repin A.A., Melnikov M.A., Kravtsov P.F.; statistical processing – Repin A.A., Kravtsov P.F.; draft manuscript preparation – Repin A.A.; manuscript revision – Katorkin S.E., Kravtsov P.F.
For citation: Katorkin S.E., Melnikov M.A., Kravtsov P.F., Repin A.A. Peculiarities of anticoagulant therapy for venous thrombosis and chronic renal insufficiency (literature review). Аngiology and Vascular Surgery. 2023; 29 (2): 170–7. DOI: https://doi.org/10.33029/1027-6661-2023-29-2-170-177 (in Russian)
References
1. Hill N.R., Fatoba S.T., Oke J.L., et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One. 2016; 11 (7): e0158765. DOI: https://doi.org/10.1371/journal.pone.0158765
2. Böttger B., Wehling M., Bauersachs R.M., et al. Prevalence of renal insufficiency in hospitalised patients with venous thromboembolic events: a retrospective analysis based on 6,725 VTE patients. Thrombosis Research. 2014; 134 (5): 1014–1019. DOI: https://doi.org/10.1016/j.thromres.2014.09.003
3. Menzorov M.V., Filimonova V.V., Erlikh A.D., et al. Renal dysfunction in patients with pulmonary embolism: data from the SIRENA register. Russian Journal of Cardiology. 2021; 26 (2S): 4422. DOI: https://doi.org/10.15829/1560-4071-2021-4422 (in Russian)
4. Goto S., Haas S., Ageno W., et al. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. JAMA Network Open. 2020; 3 (10): e2022886. DOI: https://doi.org/10.1001/jamanetworkopen.2020.22886
5. Trujillo-Santos J., Beroiz P., Moustafa F., et al. Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism. Thrombosis Research. 2020; 193: 160–165. DOI: https://doi.org/10.1016/j.thromres.2020.06.035
6. Prins M.H., Lensing A.W.A., Bauersachs R., et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal. 2013; 11: 21. DOI: https://doi.org/10.1186/1477-9560-11-21
7. Clarke M.J., Hopewell S., Juszczak E., et al. Compression stockings for preventing deep vein thrombosis in airline passengers. Cochrane Database System Rev. 2006; 2: 25–28. DOI: https://doi.org/10.1002/14651858.cd004002.pub2
8. Castillo R., Lozano T., Escolar G., et al. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood. 1986; 68: 337–342. DOI: https://doi.org/10.1182/blood.v68.2.337.bloodjournal682337
9. Sloand E.M., Sloand J.A., Prodouz K., et al. Reduction of platelet glycoprotein Ib in uremia. British Journal of Haematology. 1991; 77: 375–381. DOI: https://doi.org/10.1111/j.1365-2141.1991.tb08587.x
10. Lindahl T.L., Lundahl J., Netre C., Egberg N. Studies of the platelet fibrinogen receptor in Glanzmann patients and uremic patients. Thrombosis Research. 1992; 67: 457–466. DOI: https://doi.org/10.1016/0049-3848(92)90275-f
11. Gawaz M.P., Dobos G., Spath M., et al. Impaired function of platelet membrane glycoprotein IIb/IIIa in end-stage renal disease. Journal of the American Society of Nephrology. 1994; 5 (1): 36–46. DOI: https://doi.org/10.1681/ASN.V5136
12. Sreedhara R., Itagaki I., Hakim R.M. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb/IIa receptors. American Journal of Kidney Diseases. 1996; 27 (3): 355–364. DOI: https://doi.org/10.1016/s0272-6386(96)90358-3
13. Di Minno G., Martinez J., McKean M.L., et al. Platelet dysfunction in uremia: multifaceted defect partially corrected by dialysis. American Journal of Medicine. 1985; 79 (5): 552–559. DOI: https://doi.org/10.1016/s0022-5347(17)45901-5
14. Eknoyan G., Brown C.H.D. Biochemical abnormalities of platelets in renal failure: evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. American Journal of Nephrology. 1981; 1: 17–23. DOI: https://doi.org/10.1159/000166482
15. Walkowiak B., Pawlowska Z., Michalak E., Cierniewski C.S. Expression of fibrinogen receptors on platelets of uremic patients is correlated with the content of GP IIb and plasma level of creatinine. Journal of Thrombosis and Haemostasis. 1994; 71: 164–168. DOI: https://doi.org/10.1055/s-0038-1646607
16. Bonomini M., Dottori S., Amoroso L., et al. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. Journal of Thrombosis and Haemostasis. 2004; 2 (8): 1275–1281. DOI: https://doi.org/10.1111/j.1538-7836.2004.00837.x
17. Ando M., Iwata A., Ozeki Y., et al. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney International. 2002; 62 (5): 1757–1763. DOI: https://doi.org/10.1046/j.1523-1755.2002.00627.x
18. Tschan S., Bolliger D. Coagulation and Aging: Implications for the Anesthesiologist. Current Anesthesiology Reports. 2021; 11: 387–395. DOI: https://doi.org/10.1007/s40140-021-00498-7
19. Galdi F., Pedone C., Incalzi R.A. Thromboembolic disease: a geriatric syndrome. Journal of Gerontology and Geriatrics. 2021; 69: 68–78. DOI: https://doi.org/10.36150/2499-6564-437
20. Kakkos S.K., Gohel M., Baekgaard N., et al. European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. European Journal of Vascular and Endovascular Surgery. 2021; 61 (1): 9–82. DOI: https://doi.org/10.1016/j.ejvs.2020.09.023
21. Nieto J.A., Solano R., Ruiz-Ribo M.D., et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. Journal of Thrombosis and Haemostasis. 2010; 8 (6): 1216–1222. DOI: https://doi.org/10.1111/j.1538-7836.2010.03852.x
22. Walston J., McBurnie M.A., Newman A., et al. Cardiovascular Health Study. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Archives of Internal Medicine. 2002; 162 (20): 2333–2341. DOI: https://doi.org/10.1001/archinte.162.20.2333
23. Mazzolai L., Ageno W., Alatri A., et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. European Journal of Preventive Cardiology. 2021; 29 (8): 1248–1263. DOI: https://doi.org/10.1093/eurjpc/zwab088
24. Shioi A., Morioka T., Shoji T., et al. The Inhibitory Roles of Vitamin K in Progression of Vascular Calcification. Nutrients. 2020; 12 (2): 583. DOI: https://doi.org/10.3390/nu12020583
25. Bauersachs R.M. Use of anticoagulants in elderly patients. Thrombosis Research. 2012; 129 (2): 107–115. DOI: https://doi.org/10.1016/j.thromres.2011.09.013
26. Van der Hulle T., Koolman J., den Exter P.L., et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis. 2014; 12 (3): 320–328. DOI: https://doi.org/10.1111/jth.12485
27. Bauersachs R., Berkowitz S.D., Brenner B., et al. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine. 2010; 363 (26): 2499–2510. DOI: https://doi.org/10.1056/nejmoa1007903
28. Büller H.R., Prins M.H., Lensing A.W.A., et al. The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine. 2012; 366 (14): 1287–1297. DOI: https://doi.org/10.1056/nejmoa1113572
29. Schulman S., Kakkar A.K., Goldhaber S.Z., et al. RE-COVER II Trial Investigators: Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129 (7): 764–772. DOI: https://doi.org/10.1182/blood.v124.21.594.594
30. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine. 2009; 361: 2342–2352. DOI: https://doi.org/10.1016/j.jvn.2010.03.002
31. Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine. 2013; 369: 799–808. DOI: https://doi.org/10.1016/j.jvs.2013.11.011
32. Hokusai-VTE Investigators, Buller H.R., Decousus H., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine. 2013; 369 (15): 1406–1415. DOI: https://doi.org/10.1056/nejmoa1306638
33. Miners J.O., Yang X., Knights K.M., Zhang L. The role of the kidney in drug elimination: transport, metabolism, and the impact of kidney disease on drug clearance. Clinical Pharmacology & Therapeutics. 2017; 102 (3): 436–449. DOI: https://doi.org/10.1002/cpt.757
34. Stangier J., Rathgen K., Stähle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clinical Pharmacokinetics. 2010; 49 (4): 259–268. DOI: https://doi.org/10.2165/11318170-000000000-00000
35. Geldhof V., Vandenbriele C., Verhamme P., Vanassche T. REVIEW Open Access Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thrombosis Journal. 2014; 1: 645–658. DOI: https://doi.org/10.1186/1477-9560-12-21
36. Bauersachs R.M., Lensing A.W.A., Prins M.H., et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thrombosis Journal. 2014; 12: 25. DOI: https://doi.org/10.1186/1477-9560-12-25
37. Douketis J.D., Foster G.A., Crowther M.A., et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine. 2000; 160 (22): 3431–3436. DOI: https://doi.org/10.1001/archinte.160.22.3431
38. Limone B.L., Hernandez A.V., Michalak D., et al. Coleman timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials. Thrombosis Research. 2013; 132 (4): 420–426. DOI: https://doi.org/10.1016/j.thromres.2013.08.003
39. Konstantinides S.V. ESC guidelines for the diagnosis and treatment of acute pulmonary embolism, developed in collaboration with the European Respiratory Society (ERS), 2019. Russian Journal of Cardiology. 2020; 25 (8): 3848. DOI: https://doi.org/10.15829/1560-4071-2020-3848 (in Russian)
40. Escolar G., Carne X., Arellano-Rodrigo E. Dosing of rivaroxaban by indication: getting the right dose for the patient. Expert Opinion on Drug Metabolism & Toxicology. 2015; 11 (10): 1665–1677. DOI: https://doi.org/10.1517/17425255.2015.1085022
41. Kachkovsky M.A., Krasnoslobodskaya O.V. Adherence to drug therapy in patients with atrial fibrillation. RUDN Journal of Medicine. 2010; 448: 229–233. (in Russian)
42. Coleman C.I., Roberts M.S., Sobieraj D.M., et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Current Medical Research and Opinion. 2012; 28 (5): 669–680. DOI: https://doi.org/10.1185/03007995.2012.677419
All articles in our journal are distributed under the CC BY-NC-ND 4.0 (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International)
п?? GEOTAR-Media Publishing Group. The use of textual and illustrative content from this publication for the training of any artificial intelligence systems п?? including machine learning models and neural networks п?? is strictly prohibited without the prior written consent of the copyright holder.